+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 52 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are conducting a Phase 12a clinical trial to evaluate the safety and tolerability of DB-1311BNT324 in adults with advanced solid tumors that have progressed after standard treatments or have no available standard options. The trial aims to find the maximum tolerated dose and recommended dose for further study, as well as explore preliminary antitumor activity in selected cancers including prostate cancer. The study is multicenter, open-label, and includes a drug-drug interaction sub-study to assess the effects of other medications on DB-1311. In Phase 1, participants receive escalating single doses of DB-1311BNT324 every three weeks to determine safety and optimal dosing. Phase 2a expands dosing to confirm safety and explore effectiveness of DB-1311 given alone or combined with hormone therapies such as enzalutamide or abiraterone in prostate cancer. Treatment cycles are repeated every 21 days via intravenous infusion. Some participants receive additional oral medications to study interactions. The trial includes various cohorts with different tumor types and prior treatment histories. Participants undergo multiple assessments including safety labs, vital signs, ECGs, heart function tests, and performance status evaluations throughout treatment and for about one year after. Tumor response is measured using standard criteria, along with pharmacokinetic and immunogenicity tests. Researchers monitor adverse events and serious events continuously. The total participation lasts up to approximately one year post-treatment to evaluate safety, dosing, and preliminary outcomes.

Age: 18Years +All GendersPhase 1Phase 2
107 locations
E

Actively Recruiting

Researchers are evaluating UBT251, a new medication, in adults with type 2 diabetes to determine its effectiveness and safety. The study compares UBT251 to a placebo and also includes a comparison to semaglutide, an existing treatment for type 2 diabetes. The trial is designed as a phase 2 study to find the appropriate dose and assess treatment impact on blood sugar control. Participants will be randomly assigned to one of four groups receiving UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. Each participant will receive their assigned treatment once weekly by subcutaneous injection. The study includes a treatment period lasting up to 40 weeks, with evaluations at various points including weeks 16, 28, and 40. Throughout the study, participants will undergo regular assessments such as measuring glycated hemoglobin HbA1c to track blood sugar levels, body weight, insulin resistance, blood pressure, cholesterol, and kidney function. Safety will be monitored by recording treatment-emergent adverse events up to 46 weeks. The total participation time covers baseline, treatment, and follow-up visits to evaluate the study outcomes comprehensively.

Age: 18Years - 75YearsAll GendersPhase 2
70 locations
E

Actively Recruiting

Researchers are evaluating combination chemotherapy treatments for patients with newly diagnosed diffuse anaplastic Wilms tumors DAWT and relapsed favorable histology Wilms tumors FHWT. This phase II trial aims to compare different chemotherapy regimens to see if adding drugs like vincristine and irinotecan improves survival outcomes for these patients, based on historical data. The study also explores kidney toxicity, genetic factors, and surgical outcomes related to these tumors. Patients are assigned to one of two treatment groups. Arm I Regimen UH-3 involves multiple cycles of vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan administered intravenously every 21 days with radiation therapy as needed. Arm II Regimen ICECycloTopo includes cycles of carboplatin, etoposide, ifosfamide, cyclophosphamide, and topotecan given intravenously every 21 days with surgery andor radiation as clinically indicated. Both groups undergo various imaging scans and biopsies throughout treatment. Participants are closely monitored with CT, PET, X-rays, MRI, ultrasound, bone scans, blood tests, and biopsies during the trial. After treatment, follow-up visits occur every 3 months for the first two years, then every 6 months for years 3 and 4, and once at year 5. The primary outcomes measured are event-free survival and overall survival up to five years. The study also collects blood, urine, and tumor tissue samples for future research and monitors treatment side effects and kidney function.

Age: 0 - 30YearsAll GendersPhase 2
205 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of enpatoran in adults with active cutaneous manifestations of lupus erythematosus, with or without systemic disease, in this global, multicenter Phase 3 study. The study aims to assess enpatorans effect over 24 weeks compared to a placebo, focusing on skin disease activity and safety outcomes. Participants include those diagnosed with discoid, subacute cutaneous lupus, or active acute cutaneous lupus alongside systemic lupus erythematosus. Participants will receive either enpatoran tablets or matching placebo tablets orally twice daily for 24 weeks Day 1 to Day 168, alongside investigator-recommended standard of care. The study includes scheduled visits every 4 weeks, with a telehealth visit at Week 2. The intervention is administered as film-coated tablets, and the treatment period lasts for 24 weeks within an overall study duration of up to 35 weeks. During the study, participants will be monitored through regular visits every 4 weeks to assess skin disease using the Cutaneous Lupus Erythematosus Disease Area and Severity Index CLASI and other clinical measurements. Researchers will evaluate skin improvement, lupus disease activity, adverse events, laboratory parameters, and corticosteroid use. Safety and treatment effects will be closely followed during and after the treatment period, with the primary outcome assessed at Week 24.

Age: 18Years - 75YearsAll GendersPhase 3
74 locations
E

Actively Recruiting

Researchers are evaluating the clinical effectiveness and safety of icotrokinra in adults with moderately to severely active Crohns disease, a long-term condition causing serious inflammation in the intestines. The study is a Phase 2b3 randomized, double-blind, placebo-controlled trial aiming to better understand how well icotrokinra works in treating this condition. Participants will receive one of several oral treatments daily during an initial 12-week induction phase either one of two doses of icotrokinra or a matching placebo. After Week 12, their response status will guide further treatment. Those responding to icotrokinra may be randomized to maintenance doses for up to 40 weeks, with some eligible to join a long-term extension study. Placebo recipients who respond may continue placebo or switch to icotrokinra under specific conditions. Throughout the trial, participants will undergo regular assessments to monitor clinical response, remission, and endoscopic healing at Weeks 12 and 40. Safety will be closely followed up to four weeks after the last dose. The study measures various outcomes including patient-reported remission, inflammatory markers, quality of life, and fatigue. Total participation may extend up to several months depending on treatment phase and eligibility for long-term follow-up.

Age: 18Years +All GendersPhase 2Phase 3
395 locations
L

Actively Recruiting

Heart attacks occur when a blood clot blocks the hearts blood vessels, stopping blood flow to the heart muscle. This trial focuses on patients with ST-elevation myocardial infarction STEMI and looks at how microcirculatory damage can be measured using the Index of Microcirculatory Resistance IMR. The study aims to find out if treating patients with impaired microcirculatory perfusion using low-dose intracoronary thrombolytic therapy can reduce heart muscle damage and improve clinical outcomes. Participants who have had a heart attack and undergone angioplasty will have their IMR measured. Those with an IMR above 32 will be randomly assigned to receive either low-dose tenecteplase a clot-dissolving drug or a placebo sterile water administered directly into the coronary artery. Patients with lower IMR will be followed in a registry. The treatment is given as an intracoronary infusion over 3 minutes. Cardiac enzymes, MRI scans, and other heart function tests will be done at various time points. During the study, participants will have heart enzyme tests at hospital admission and discharge. Those in the randomised group will receive cardiac MRI scans at discharge and six months later. Follow-up visits will occur at 30 days, then 6, 12, and 24 months after discharge to monitor heart function, rehospitalisation, and mortality. The main outcomes measured include cardiovascular death, heart failure rehospitalisation, heart attack size, and bleeding events, with safety and efficacy monitored closely throughout the study period.

Age: 18Years +All GendersPhase 3
22 locations
E

Actively Recruiting

Researchers are evaluating how well a lower dose of radiotherapy after chemotherapy works to treat children and young adults with central nervous system CNS germinomas. This Phase II study focuses on using carboplatin and etoposide chemotherapy followed by reduced radiation doses to see if this approach can effectively control the disease while potentially reducing long-term side effects. The study also investigates neuroendocrine function and cognitive processing speed as important outcomes. Participants receive up to four cycles of chemotherapy with carboplatin given intravenously on day 1 and etoposide given intravenously on days 1 through 3 every 21 days. After chemotherapy, patients are assigned to different treatment groups based on their response and tumor characteristics. Radiation therapy options include 3-dimensional conformal radiation, intensity-modulated radiation, or proton therapy with varying doses depending on the specific group. Some patients may undergo second-look surgery to assess tumor response. Blood, cerebrospinal fluid, and tissue samples may be collected throughout the study for further research. During the study, participants undergo regular magnetic resonance imaging MRI scans and may have lumbar punctures for cerebrospinal fluid collection during screening and follow-up. They are monitored for event-free survival, overall survival, tumor response, neuroendocrine function, and cognitive processing speed over several years. Follow-up visits occur every 3 months for the first year, then every 4 months for two years, followed by annual visits for up to 10 years after treatment. This allows researchers to assess long-term effects and outcomes.

Age: 3Years - 29YearsAll GendersPhase 2
115 locations
I

Actively Recruiting

Researchers are evaluating the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy to treat children, adolescents, and young adults with Philadelphia chromosome positive Ph or ABL-class Philadelphia chromosome-like Ph-like B-cell acute lymphoblastic leukemia B-ALL. This phase 2 trial aims to estimate event-free survival, overall survival, and safety profiles, including infections and neurotoxicity, over three years in these patients. The study also explores minimal residual disease negativity, immune function, and drug levels in the plasma and cerebrospinal fluid to better understand treatment response and outcomes. Participants receive a complex treatment plan based on their leukemia subtype. Those with Ph B-ALL receive a modified chemotherapy backbone combined with dasatinib and three cycles of blinatumomab, while patients with ABL-class Ph-like B-ALL receive similar chemotherapy with imatinib or dasatinib depending on gene fusion type. Treatment includes multiple phases such as induction, blinatumomab blocks, interim maintenance, delayed intensification, and maintenance cycles over about two years. Additional therapies like radiation, intrathecal methotrexate, and various chemotherapy drugs are also given as part of the regimen. Throughout the study, participants undergo regular evaluations including echocardiography or multigated acquisition scans during screening, as well as blood and cerebrospinal fluid collection and bone marrow biopsies at various points. Researchers closely monitor disease status, adverse events, and minimal residual disease using advanced tests. The primary outcomes measure event-free survival and adverse events up to three years, with secondary outcomes including overall survival and relapse rates. Participants remain under observation for safety and treatment response during the entire course of therapy.

Age: 366Days - 46YearsAll GendersPhase 2
161 locations
S

Actively Recruiting

This research aims to evaluate the safety and effectiveness of Mirvetuximab Soravtansine in female participants aged 18 years and older who have platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high levels of folate receptor alpha FR. The study includes two groups a randomized Phase 2 group and a hepatic impairment group, with about 110 participants expected worldwide. The purpose is to better understand how this investigational antibody drug conjugate works by targeting cancer cells carrying FR to deliver a cell-killing drug. Participants in the randomized Phase 2 group receive Mirvetuximab Soravtansine intravenously on one of two schedules either a standard dose on day 1 every 21 days or a lower dose on days 1 and 15 every 28 days. The hepatic impairment group evaluates the starting dose for participants with moderately abnormal liver function, receiving different doses on day 1 of a 21-day cycle. Treatment and monitoring continue for up to about 24 months, including dose optimization and safety assessments. During the study, participants will visit the hospital or clinic regularly for medical exams, blood tests, and scans to track treatment effects and side effects. Researchers will measure responses including corneal adverse events, tumor response rates, drug concentrations in the body, and survival outcomes. Safety is closely monitored through assessments of vital signs, laboratory values, and physical exams. The total participation time is approximately 24 months, with ongoing evaluations to determine how well the treatment works and its safety profile.

Age: 18Years +FEMALEPhase 2
52 locations
P

Actively Recruiting

This research aims to evaluate the effectiveness and safety of plixorafenib in participants with cancers that have specific BRAF gene alterations. These include locally advanced or metastatic solid tumors, primary central nervous system tumors, and rare BRAF V600E-mutated solid tumors such as anaplastic thyroid, ovarian, and cholangiocarcinoma cancers. The study focuses on participants with BRAF V600E mutations or BRAF fusions and seeks to understand treatment effects across various cancer types. Participants receive plixorafenib orally in continuous 3-week cycles. Dosing may be increased as tolerated and continues until disease progression, unacceptable side effects, or withdrawal for other reasons. The study includes different subprotocols tailored to tumor type and BRAF alteration, such as unresectable solid tumors with BRAF fusions, recurrent primary CNS tumors with BRAF V600E mutations, rare non-CNS solid tumors with BRAF V600E mutations, and other advanced solid tumors with BRAF V600E mutations. Participants will undergo scans before starting treatment to assess tumor changes, and regular monitoring will continue during treatment. Researchers will evaluate tumor response, progression-free survival, overall survival, treatment safety, and drug levels in the blood over up to approximately four years. The study tracks side effects and collects detailed pharmacokinetic data to understand how the drug is processed. Participants remain in the study until disease progression or other withdrawal criteria are met, with ongoing safety and efficacy assessments.

Age: 8Years +All GendersPhase 2
70 locations

1-10 of 52

1